CHEST:CHEST指南对成人咳嗽的全新评估!

2017-11-02 MedSci MedSci原创

近期,一篇发表在杂志CHEST上的文章使用了PICO格式进行系统评价,回答了以下关键临床问题:2006年CHEST根据咳嗽持续时间而对成年人急性、亚急性和慢性咳嗽分类以及相关管理算法的分类是否有用?研究者们使用了CHEST专家咳嗽小组的系统评价方案和美国胸科医师学会(CHEST)方法学指南以及GRADE框架。系统评价结合患者价值观和偏好以及临床背景的数据用于形成建议。使用德尔菲方法获得最终的分级。

近期,一篇发表在杂志CHEST上的文章使用了PICO格式进行系统评价,回答了以下关键临床问题:2006年CHEST根据咳嗽持续时间而对成年人急性、亚急性和慢性咳嗽分类以及相关管理算法的分类是否有用?


研究者们使用了CHEST专家咳嗽小组的系统评价方案和美国胸科医师学会(CHEST)方法学指南以及GRADE框架。系统评价结合患者价值观和偏好以及临床背景的数据用于形成建议。使用德尔菲方法获得最终的分级。

此项研究结果显示:关于急性咳嗽(<3周),仅有3项研究符合质量评估标准,均具有较高的偏倚风险。根据2006年CHEST 咳嗽指南的预测,最常见的原因是呼吸道感染,最有可能的病因是病毒,其次是哮喘和慢性阻塞性肺疾病以及肺炎等基础疾病的恶化。受试者居住在3大洲,北美、欧洲和亚洲。

对于亚急性咳嗽(3-8周),仅有2项研究符合质量评估标准,均具有较高的偏倚风险。如2006年指南所预测,最常见的原因是感染性咳嗽和基础疾病如哮喘、COPD和上呼吸道咳嗽综合征的恶化。受试者居住在亚洲国家。

关于慢性咳嗽(> 8周),11项研究符合质量评估标准,均具有较高的偏倚风险。如2006年指南所预测的,最常见的原因是鼻窦病情、哮喘、胃食管反流病、非哮喘嗜酸粒细胞性支气管炎的上呼吸道咳嗽综合征,以及这4种的组合,较不常见的是各种杂病和特应性咳嗽。受试者居住在北美、南美、欧洲和亚洲四大洲。

此项研究结果表明:虽然研究证据质量较差,但自2006年以来发表的文献表明,CHEST组织2006年“咳嗽指南”和成人急性、亚急性和慢性咳嗽的管理算法可用于诊断和治疗全球咳嗽患者。这些相同的算法已经更新,并将反映到2017年咳嗽管理的进展中。

原始出处:
Irwin RS, French CL, et al. Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report. Chest. 2017 Oct 25. pii: S0012-3692(17)32918-5. doi: 10.1016/j.chest.2017.10.016. 

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2050888, encodeId=e7822050888dc, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Jul 06 00:57:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929433, encodeId=3c84192943359, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Sep 09 18:57:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258209, encodeId=788c258209b1, content=学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Nov 03 00:33:49 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258189, encodeId=bba7258189d3, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6831717982, createdName=微分, createdTime=Thu Nov 02 23:34:57 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258124, encodeId=56512581242b, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Nov 02 21:05:20 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2050888, encodeId=e7822050888dc, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Jul 06 00:57:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929433, encodeId=3c84192943359, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Sep 09 18:57:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258209, encodeId=788c258209b1, content=学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Nov 03 00:33:49 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258189, encodeId=bba7258189d3, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6831717982, createdName=微分, createdTime=Thu Nov 02 23:34:57 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258124, encodeId=56512581242b, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Nov 02 21:05:20 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
    2018-09-09 Smile2680
  3. [GetPortalCommentsPageByObjectIdResponse(id=2050888, encodeId=e7822050888dc, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Jul 06 00:57:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929433, encodeId=3c84192943359, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Sep 09 18:57:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258209, encodeId=788c258209b1, content=学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Nov 03 00:33:49 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258189, encodeId=bba7258189d3, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6831717982, createdName=微分, createdTime=Thu Nov 02 23:34:57 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258124, encodeId=56512581242b, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Nov 02 21:05:20 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
    2017-11-03 飛歌

    学习天天向上

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2050888, encodeId=e7822050888dc, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Jul 06 00:57:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929433, encodeId=3c84192943359, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Sep 09 18:57:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258209, encodeId=788c258209b1, content=学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Nov 03 00:33:49 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258189, encodeId=bba7258189d3, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6831717982, createdName=微分, createdTime=Thu Nov 02 23:34:57 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258124, encodeId=56512581242b, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Nov 02 21:05:20 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
    2017-11-02 微分

    学习了新知识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2050888, encodeId=e7822050888dc, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Jul 06 00:57:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929433, encodeId=3c84192943359, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Sep 09 18:57:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258209, encodeId=788c258209b1, content=学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Nov 03 00:33:49 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258189, encodeId=bba7258189d3, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6831717982, createdName=微分, createdTime=Thu Nov 02 23:34:57 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258124, encodeId=56512581242b, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Nov 02 21:05:20 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
    2017-11-02 Y—xianghai

    学习了新知识

    0

相关资讯

Chest:钟南山等研究发现罗氟司特为重度至极重度亚裔COPD患者理想的治疗药物

罗氟司特是可用于治疗慢性阻塞性肺疾病(COPD)的唯一口服磷酸二酯酶4抑制剂。以往有关该药的研究主要在欧洲和北美国家的人群中进行。为了明确在以华人为主的此类人群中,使用罗氟司特的有效性和安全性。来自广州医科大学第一附属医院、广州呼吸疾病研究所的钟南山研究团队进行了一项研究,研究结果在线发表于2013年10月17日的CHEST杂志上。结果显示:罗氟司特治疗能明显改善亚裔COPD患者的肺功能,并具有很

Chest:FF/VI每日一次吸入与FP/SAL每日两次吸入治疗持续性哮喘的效果相当

糠酸氟替卡松(FF)是一种新型的吸入性糖皮质激素(ICS),而维兰特罗(VI)则是一种长效β2受体激动剂,作为一个研发之中的、每日只需用药一次的治疗方法,FF与VI(FF/VI)组合正被越来越多地用于支气管哮喘和慢性阻塞性肺疾病(COPD)的治疗。 为了比较FF/VI组合、与丙酸氟替卡松(FP)/沙美特罗(SAL)组合(FP/SAL),对于吸入中等量激素仍难以控制的持续哮喘患者的疗效,来自英国南

Chest:在现行HHT诊断标准中加入超声心动图指标可明显提高其诊断准确性

根据遗传性出血性毛细血管扩张症(HHT)的Curaçao诊断标准,该病的临床诊断依据主要有四条,其中之一就是需有肺动静脉畸形(PAVM)的存在。近几年来,经胸超声心动图(TTCE)已经取代胸部高分辨率CT(HRCT)而成为PAVM的重要筛查手段,为了评估是否任何经TTCE发现的肺动静脉畸形都可以作为HHT的Curaçao标准中的一条新指标,来自荷兰纽威海恩市圣安医院心内科的S.Velthuis博士

CHEST:成年支气管哮喘患者的死亡率明显增加

对于诊断明确的支气管哮喘(哮喘)患者而言,其相关的长期随访研究数据目前比较有限。为了加深对这一问题的认识,来自丹麦哥本哈根大学哈维德夫医院肺内科的Charlotte Suppli Ulrik及其同事进行了一项研究,研究结果在线发表于2013年3月7日的《CHEST》杂志上。该研究结果显示:与相匹配的对照组相比,诊断明确的成年哮喘患者的死亡率增加,而且这种增加在很大程度上,可以用继发于哮喘的阻塞性肺

Chest:支气管哮喘的高乳酸血症不影响患者的预后

支气管哮喘发作时患者高乳酸血症的发病率、及其发生原因,目前仍无定论,为了加深对这一问题的认识,来自美国密苏里州华盛顿大学-圣路易斯医学院急诊医学科的Lawrence M. Lewis及其同事进行了一项研究,研究结果在线发表于2013年8月15日的CHEST杂志上。研究显示:支气管哮喘患者血浆中沙丁胺醇的浓度与其血清中乳酸的浓度具有显著的相关性。但高乳酸血症与患者接受治疗3小时后较差的FEV1%测量

Chest:肺部感染或误吸是树芽征常见的成因

据报道,可以导致患者胸部CT上出现树芽状阴影(树芽征,TIB)的原因有很多,但对于这些原因在树芽征形成时出现的相对频率,此前还没有相应的研究。为了在病因学方面明确树芽征各病因出现的相对频率,并确定疾病类型与树芽征的相互关系,来自美国费城宾夕法尼亚大学医学中心的Wallace T. Miller, Jr.及其同事进行了一项研究,研究结果在线发表于2013年8月15日的CHEST杂志上。研究显示:肺部